Feasibility and Assessment of a Cascade Traceback Screening Program (FACTS): Protocol for a Multisite Study to Implement and Assess an Ovarian Cancer Traceback Cascade Testing Program.
HIPAA
genetic testing
implementation
implementation research
micro-costing
ovarian cancer
traceback cascade testing program
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
11 Jun 2021
11 Jun 2021
Historique:
received:
30
04
2021
revised:
06
06
2021
accepted:
08
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Ovarian cancer (OVCA) patients may carry genes conferring cancer risk to biological family; however, fewer than one-quarter of patients receive genetic testing. "Traceback" cascade testing -outreach to potential probands and relatives-is a possible solution. This paper outlines a funded study (U01 CA240747-01A1) seeking to determine a Traceback program's feasibility, acceptability, effectiveness, and costs. This is a multisite prospective observational feasibility study across three integrated health systems. Informed by the Conceptual Model for Implementation Research, we will outline, implement, and evaluate the outcomes of an OVCA Traceback program. We will use standard legal research methodology to review genetic privacy statutes; engage key stakeholders in qualitative interviews to design communication strategies; employ descriptive statistics and regression analyses to evaluate the site differences in genetic testing and the OVCA Traceback testing; and assess program outcomes at the proband, family member, provider, system, and population levels. This study aims to determine a Traceback program's feasibility and acceptability in a real-world context. It will account for the myriad factors affecting implementation, including legal issues, organizational- and individual-level barriers and facilitators, communication issues, and program costs. Project results will inform how health care providers and systems can develop effective, practical, and sustainable Traceback programs.
Identifiants
pubmed: 34208188
pii: jpm11060543
doi: 10.3390/jpm11060543
pmc: PMC8230764
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : U01 CA240747
Pays : United States
Organisme : NIH HHS
ID : U01 CA240747-01A1
Pays : United States
Références
JAMA Oncol. 2021 Feb 1;7(2):230-237
pubmed: 33126242
Eur J Cancer. 2016 Dec;69:127-134
pubmed: 27821315
Am J Surg. 2009 Oct;198(4):562-5
pubmed: 19800469
J Clin Oncol. 2017 Jul 10;35(20):2329-2337
pubmed: 28398847
BMJ. 2000 Jan 8;320(7227):114-6
pubmed: 10625273
JAMA. 2009 Apr 1;301(13):1373-5
pubmed: 19336713
Genet Med. 2021 Jun;23(6):1004-1007
pubmed: 33649579
Cancer. 2017 Jul 1;123(13):2497-2505
pubmed: 28182268
Int J Technol Assess Health Care. 2013 Apr;29(2):117-22
pubmed: 23587340
Adm Policy Ment Health. 2011 Mar;38(2):65-76
pubmed: 20957426
J Med Ethics. 2007 Jul;33(7):390-3
pubmed: 17601865
Gynecol Oncol. 2013 Aug;130(2):329-33
pubmed: 23707676
Genet Med. 2009 Sep;11(9):655-62
pubmed: 19752639
Adm Policy Ment Health. 2009 Jan;36(1):24-34
pubmed: 19104929
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
J Community Genet. 2013 Apr;4(2):233-42
pubmed: 23319393
J Natl Compr Canc Netw. 2020 Apr;18(4):380-391
pubmed: 32259785
CA Cancer J Clin. 2002 May-Jun;52(3):134-49
pubmed: 12018928
PLoS One. 2018 Jul 12;13(7):e0200559
pubmed: 30001421
J Health Commun. 2016;21(3):346-55
pubmed: 26735646
Gynecol Oncol. 2015 Jan;136(1):3-7
pubmed: 25238946
Adv Ther. 2016 Feb;33(2):129-50
pubmed: 26809252
J Clin Oncol. 2019 May 20;37(15):1305-1315
pubmed: 30964716
Ann Intern Med. 2014 Feb 18;160(4):255-66
pubmed: 24366442
Health Aff (Millwood). 2018 May;37(5):801-808
pubmed: 29733730